Tweet
NSAIDs Protect Against Parkinson's Disease
(HealthDay News) -- Taking over-the-counter pain medicines called non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of Parkinson's disease, according to a study by researchers at the UCLA School of Public Health in Los Angeles.
The study included 579 men and women (half with Parkinson's disease) who were asked if they'd taken aspirin or non-aspirin NSAIDs (such as ibuprofen) once a week or more for at least a month at any time in their lives.
Those who took two or more pills (either aspirin or a non-aspirin NSAID) a week for at least a month were classified as regular users, while those who took fewer pills were non-regular users.
Compared to non-users and non-regular users, regular users of non-aspirin NSAIDs reduced their risk of Parkinson's by as much as 60 percent, the study found. Women who were regular users of aspirin reduced their risk of Parkinson's by 40 percent, especially those who were regular users of aspirin for more than two years.
The study is published in the Nov. 6 issue of Neurology.
(HealthDay News) -- Taking over-the-counter pain medicines called non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of Parkinson's disease, according to a study by researchers at the UCLA School of Public Health in Los Angeles.
The study included 579 men and women (half with Parkinson's disease) who were asked if they'd taken aspirin or non-aspirin NSAIDs (such as ibuprofen) once a week or more for at least a month at any time in their lives.
Those who took two or more pills (either aspirin or a non-aspirin NSAID) a week for at least a month were classified as regular users, while those who took fewer pills were non-regular users.
Compared to non-users and non-regular users, regular users of non-aspirin NSAIDs reduced their risk of Parkinson's by as much as 60 percent, the study found. Women who were regular users of aspirin reduced their risk of Parkinson's by 40 percent, especially those who were regular users of aspirin for more than two years.
The study is published in the Nov. 6 issue of Neurology.
Comment